Deutsche Bank Ag\ Replimune Group, Inc. Transaction History

Deutsche Bank Ag\

$245 Billion
Q1 2025

A detailed history of Deutsche Bank Ag\ transactions in Replimune Group, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 563,701 shares of REPL stock, worth $5.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

563,701

Previous 561,561 0.38%

Holding current value

$5.26 Million

Previous $6.8 Million 19.18%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	BUY	$9.75 - $14.31 $20,865 - $30,623	2,140 Added 0.38%	563,701 $5.5 Million
Q4 2024 Feb 14, 2025	BUY	$10.54 - $14.93 $273,207 - $387,000	25,921 Added 4.84%	561,561 $6.8 Million
Q3 2024 Jun 26, 2025	SELL	$8.09 - $11.23 $227,013 - $315,125	-28,061 Reduced 4.98%	535,640 $5.87 Million
Q3 2024 Nov 13, 2024	BUY	$8.09 - $11.23 $60,707 - $84,269	7,504 Added 1.42%	535,640 $5.87 Million
Q2 2024 Jun 12, 2025	SELL	$5.01 - $9.46 $178,180 - $336,444	-35,565 Reduced 6.31%	528,136 $4.75 Million
Q2 2024 Aug 14, 2024	BUY	$5.01 - $9.46 $30,510 - $57,611	6,090 Added 1.17%	528,136 $4.75 Million
Q1 2024 Jun 02, 2025	SELL	$6.87 - $9.31 $286,169 - $387,808	-41,655 Reduced 7.39%	522,046 $4.27 Million
Q1 2024 May 15, 2024	BUY	$6.87 - $9.31 $2.64 Million - $3.58 Million	384,267 Added 278.9%	522,046 $4.27 Million
Q4 2023 Feb 14, 2024	BUY	$6.75 - $16.18 $803,729 - $1.93 Million	119,071 Added 636.47%	137,779 $1.16 Million
Q3 2023 Nov 09, 2023	SELL	$15.96 - $22.18 $1.86 Million - $2.59 Million	-116,726 Reduced 86.19%	18,708 $320,000
Q2 2023 Aug 14, 2023	SELL	$15.65 - $24.1 $251,839 - $387,817	-16,092 Reduced 10.62%	135,434 $3.14 Million
Q1 2023 May 15, 2023	BUY	$17.48 - $29.09 $176,897 - $294,390	10,120 Added 7.16%	151,526 $2.68 Million
Q4 2022 Feb 13, 2023	BUY	$17.09 - $27.91 $85,706 - $139,968	5,015 Added 3.68%	141,406 $3.85 Million
Q3 2022 Nov 14, 2022	BUY	$15.6 - $21.15 $25,365 - $34,389	1,626 Added 1.21%	136,391 $2.36 Million
Q2 2022 Aug 11, 2022	SELL	$13.32 - $19.98 $34,658 - $51,987	-2,602 Reduced 1.89%	134,765 $2.36 Million
Q1 2022 May 13, 2022	BUY	$15.24 - $29.75 $1.79 Million - $3.5 Million	117,655 Added 596.87%	137,367 $2.33 Million
Q4 2021 Feb 11, 2022	SELL	$25.43 - $34.25 $1.77 Million - $2.38 Million	-69,486 Reduced 77.9%	19,712 $534,000
Q3 2021 Nov 04, 2021	BUY	$28.98 - $39.54 $35,065 - $47,843	1,210 Added 1.38%	89,198 $2.64 Million
Q2 2021 Aug 11, 2021	SELL	$28.5 - $39.37 $382,641 - $528,581	-13,426 Reduced 13.24%	87,988 $3.38 Million
Q1 2021 May 13, 2021	SELL	$30.22 - $45.57 $4.4 Million - $6.63 Million	-145,474 Reduced 58.92%	101,414 $3.09 Million
Q4 2020 Feb 16, 2021	BUY	$23.5 - $52.65 $5.54 Million - $12.4 Million	235,606 Added 2088.34%	246,888 $9.42 Million
Q3 2020 Nov 12, 2020	BUY	$18.85 - $27.0 $47,709 - $68,337	2,531 Added 28.92%	11,282 $260,000
Q2 2020 Aug 13, 2020	BUY	$9.76 - $25.95 $41,997 - $111,662	4,303 Added 96.74%	8,751 $218,000
Q1 2020 May 14, 2020	SELL	$8.9 - $19.08 $39,605 - $84,905	-4,450 Reduced 50.01%	4,448 $45,000
Q4 2019 Feb 14, 2020	BUY	$11.61 - $17.21 $63,042 - $93,450	5,430 Added 156.57%	8,898 $126,000
Q3 2019 Nov 14, 2019	SELL	$10.01 - $16.87 $42,772 - $72,085	-4,273 Reduced 55.2%	3,468 $46,000
Q2 2019 Aug 14, 2019	SELL	$12.51 - $17.28 $62,562 - $86,417	-5,001 Reduced 39.25%	7,741 $110,000
Q1 2019 May 15, 2019	BUY	$10.26 - $16.24 $61,241 - $96,936	5,969 Added 88.13%	12,742 $192,000
Q4 2018 Feb 14, 2019	SELL	$9.97 - $15.57 $101,733 - $158,876	-10,204 Reduced 60.1%	6,773 $66,000
Q3 2018 Dec 21, 2021	BUY	$14.99 - $22.14 $29,560 - $43,660	1,972 Added 13.14%	16,977 $273,000
Q3 2018 Nov 14, 2018	BUY	$14.99 - $22.14 $224,924 - $332,210	15,005 New	15,005 $240,000

Others Institutions Holding REPL

# of Institutions

172

Shares Held

78.5M

Call Options Held

69.4K

Put Options Held

216K

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $460M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account